How well does Alpelisib(PIQRAY) work?
A summary of the clinical trial results demonstrating the drug's effectiveness.
Clinical Benefits
In the SOLAR-1 trial, PIQRAY plus fulvestrant demonstrated a statistically significant improvement in progression-free survival (PFS) compared to placebo plus fulvestrant in patients with PIK3CA-mutated tumors. The median PFS was 11.0 months vs. 5.7 months. The combination also showed a higher overall response rate (ORR) of 35.7% compared to 16.2% in the placebo arm.
